BAKER BROS. ADVISORS LPBAKER BROS. ADVISORS LP

Institutional investor · Portfolio as of Q3 2025

Top Holdings91 positions

Checking export access…
Activity:
ONCONC
ADR

BEONE MEDICINES LTD

8.8M$3B21.7%$149.70+127.59%
27 qtrssince 2019-Q1
Unchanged
0

INCYTE CORP

30.7M$2.6B18.8%$84.99-0.21%
27 qtrssince 2019-Q1
Increased
62

MADRIGAL PHARMACEUTICALS INC

2.1M$982.3M7.1%$167.08+174.51%
27 qtrssince 2019-Q1
Increased
67

INSMED INC

6.7M$965.4M7.0%$76.23+88.91%
27 qtrssince 2019-Q1
Decreased
0

ACADIA PHARMACEUTICALS INC

42.9M$915.4M6.6%$27.48-22.36%
27 qtrssince 2019-Q1
Unchanged
0

SUMMIT THERAPEUTICS INC

33.7M$696.7M5.0%$11.80+79.38%
6 qtrssince 2024-Q2
Unchanged
0

RHYTHM PHARMACEUTICALS INC

5.6M$566M4.1%$24.17+317.91%
27 qtrssince 2019-Q1
Unchanged
0

REVOLUTION MEDICINES INC

9.5M$441.6M3.2%$30.05+53.32%
19 qtrssince 2021-Q1
Increased
58

CELCUITY INC

7.9M$391M2.8%$25.54+103.85%
9 qtrssince 2023-Q3
Increased
72

KYMERA THERAPEUTICS INC

6.7M$376.5M2.7%$29.76+90.18%
21 qtrssince 2020-Q3
Unchanged
0

KODIAK SCIENCES INC

17.3M$283.4M2.0%$34.00-51.85%
27 qtrssince 2019-Q1
Unchanged
0

ALKERMES PLC

8.1M$242.7M1.8%$26.73+12.22%
6 qtrssince 2024-Q2
Increased
60

ABCELLERA BIOLOGICS INC

27.5M$138.5M1.0%$18.96-74.32%
20 qtrssince 2020-Q4
Unchanged
0

EDGEWISE THERAPEUTICS INC

7.3M$118.5M0.9%$15.71+0.26%
19 qtrssince 2021-Q1
Unchanged
0

KINIKSA PHARMACEUTICALS INTL

2.8M$109.7M0.8%$18.69+107.76%
6 qtrssince 2024-Q2
Unchanged
0

STOKE THERAPEUTICS INC

4.6M$108.9M0.8%$11.06+123.62%
13 qtrssince 2022-Q3
Unchanged
0

IMMATICS N.V

12.1M$103M0.7%$8.87-10.80%
21 qtrssince 2020-Q3
Increased
50

GRAIL INC

1.6M$96.4M0.7%$18.64+215.29%
4 qtrssince 2024-Q4
Unchanged
0

IDEAYA BIOSCIENCES INC

3.3M$89.1M0.6%$21.71+25.24%
13 qtrssince 2022-Q3
Increased
59

IMMUNOVANT INC

5.5M$88M0.6%$21.82-26.40%
9 qtrssince 2023-Q3
Unchanged
0
$13.8B
AUM
91
Positions
Q3 2025
Filing
HI score · 3.0/5
Quarterly 13F Value Change
-2%Q2'24$7.8B+23%Q3'24$9.6B-3%Q4'24$9.4B-3%Q1'25$9B+14%Q2'25$10.3B+34%Q3'25$13.8B
Activity profile
$ moved · Q3'25
New10%Increased76%Decreased10%Exited3%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.0 years
<1Q9%1-4Q18%1-2Y16%2Y+57%

BAKER BROS. ADVISORS LP manages $13.8B across 91 positions as of Q3 2025. Top holdings: ONC (21.7%), INCY (18.8%), MDGL (7.1%). Fund DNA: Concentrated Value. HoldingsIntel Score: 3/5.0.

Q3 2025 Summary

Active quarter - 12 new positions, 10 exits, 14 increased. Top move: CELC (INCREASED, conviction 72). Portfolio: $13.8B across 91 positions.

Top holdings by portfolio weight

Total AUM$14B
ONC21.66%
INCY18.84%
MDGL7.10%
INSM6.98%
ACAD6.61%
SMMT5.03%
RYTM4.09%
RVMD3.19%
CELC2.83%
KYMR2.72%
Other2.05%

Portfolio allocation by GICS sector

Sectors2
Healthcare99.89%
Unknown0.11%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(3.0 / 5.0)
Holdings P&L46
Conviction36
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
INCYINCYINCYTE CORP
Q4 2024 → Q2 2026+23,310 shares+$1.5B
5Q
IDYAIDYAIDEAYA BIOSCIENCES INC
Q2 2025 → Q2 2026+3.9M shares+$169.3M
3Q
DSGNDSGNDESIGN THERAPEUTICS INC
Q4 2025 → Q2 2026+965,548 shares+$25.9M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used